Platelet-boosting drug for solid tumor patients with low platelets
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You received cancer treatment (chemotherapy, targeted therapy, or immunotherapy) in the last 14 days
- Your platelet count has been below 75 on two separate tests, taken more than 24 hours apart, within the last 3 days
- You have not used similar platelet-raising drugs before
- You do not have a history of blood cancers like leukemia or lymphoma
- You do not have serious liver problems or a history of blood clots that require blood thinners
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This trial tests a medicine called Romiplostim N01 to help raise platelet levels in people with solid tumors who have low platelets from chemo, radiation, or immunotherapy. The goal is to see if it can safely improve platelet counts so patients can continue their cancer treatment.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This trial tests two ways to raise platelets for people with immune thrombocytopenia (ITP) who did not respond well to a short course of the platelet-boosting drug rhTPO. One group gets a higher dose of rhTPO, the other switches to a different oral medication, eltrombopag. The goal is to see which approach works better to increase platelet counts safely.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial tests if rhTPO (a protein that boosts platelet production) can help collect enough stem cells for your own stem cell transplant. It is for people with acute leukemia who are in remission with no detectable cancer cells left.
Hear when a new CTIT-Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.